Scientist I, Investigative Toxicology

Revolution Medicines•Redwood City, CA

4d•$119,000 - $149,000•Onsite

About The Position

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a highly motivated, discovery-driven Scientist/Toxicologist to develop investigative safety strategies to identify and predict hazard early, elucidate mechanisms of toxicity, enable the advancement of portfolio programs, and improve safety translation to the clinic. The successful candidate will bring a strong investigative and problem-solving mindset and deliver bespoke predictive models of toxicity that complement traditional nonclinical safety assessment strategies. Further, the successful candidate will: Develop and deliver novel approach methods (NAMs) including predictive 2D and 3D models for nonclinical safety assessments. Design and develop in silico, in vitro/ex vivo 2D and 3D assays to detect and derisk toxicities for small molecules and emerging modalities. Assess and adopt new technologies to support improved toxicity prediction, compound screening, and development of translational/safety biomarkers. Design, analyze and oversee in vivo studies/models to better understand mechanisms of toxicity and help develop mitigation strategies. Partner with internal and external collaborators and stakeholders to support integrated large-scale data analytics, Quantitative Systems Toxicology (QST), computational and chemical mining efforts. Effectively implement and oversee studies outsourced to CROs, in collaboration with RevMed study operations, pharmacology, DMPK and clinical pharmacology functions. Be an independent scientific thinker, able to independently analyze, interpret, and summarize nonclinical safety data, and present contextualized findings with recommendations to internal project teams and RevMed leadership. Ensure timely and accurate data analysis and communication to enable decision-making, and author high-quality study reports.

Requirements

Ph.D. degree in Toxicology, Cancer Biology, Immunology, Systems Biology or related discipline with 0-2 years of relevant biotech/pharma drug discovery/development experience in a team-facing role.
Strong scientific background and scientific aptitude, with excellent critical thinking and creative problem-solving skills.
Ability to work effectively, independently and collaboratively on cross-functional teams; demonstrated ability to multitask, prioritize options, anticipate challenges, and execute on goals as a member of an interdisciplinary team is extremely important.
Experience with advanced cell culture techniques for immortalized cell lines, primary cells (including PBMCs) and/or iPSC cells.
Cell and molecular biology methods, including flow cytometry, Luminex/MSD, ELISA, and various omics platforms, including transcriptomics, NGS and/or proteomics, and data analytics utilizing bioinformatic approaches such as Python or R.
Excellent verbal, oral and written communication skills.
Strong interpersonal and organizational skills.
Thrives in a collaborative team setting and is driven by a desire to be innovative in a high energy, biotech company environment.

Nice To Haves

Expertise designing & delivering fit for purpose assays for understanding the mechanism of toxicity of agents including small molecule drugs, for biomarker development and application, and for derisking drug candidates.
Experience working with small molecules and targeted oncology therapeutics of all modalities.
Expertise in 3D cell culture systems such as tumor spheroids, organoids, complex in vitro models and organ-on-a-chip models is a plus.
Experience working in a matrixed team environment at a biotech/pharma company or CRO.
Familiarity with GLPs and FDA/ICH guidance documents for nonclinical toxicology is desirable.

Responsibilities

Develop and deliver novel approach methods (NAMs) including predictive 2D and 3D models for nonclinical safety assessments.
Design and develop in silico, in vitro/ex vivo 2D and 3D assays to detect and derisk toxicities for small molecules and emerging modalities.
Assess and adopt new technologies to support improved toxicity prediction, compound screening, and development of translational/safety biomarkers.
Design, analyze and oversee in vivo studies/models to better understand mechanisms of toxicity and help develop mitigation strategies.
Partner with internal and external collaborators and stakeholders to support integrated large-scale data analytics, Quantitative Systems Toxicology (QST), computational and chemical mining efforts.
Effectively implement and oversee studies outsourced to CROs, in collaboration with RevMed study operations, pharmacology, DMPK and clinical pharmacology functions.
Be an independent scientific thinker, able to independently analyze, interpret, and summarize nonclinical safety data, and present contextualized findings with recommendations to internal project teams and RevMed leadership.
Ensure timely and accurate data analysis and communication to enable decision-making, and author high-quality study reports.